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1 |  INTRODUCTION
Early detection of breast cancer by mammography screening has 
reduced breast cancer mortality. In both the United States and 
Europe, official guidelines recommend biennial screening for 
women aged 50 to 69 or 74 years, but starting age at 40 years is 
also quite common.1,2 At the population level, we show a 20% 
reduction in breast cancer mortality in Danish women invited 
to a population-based screening program.3 Nevertheless, sub-
groups of women may contribute very differently to this average.
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Abstract
Background: Although breast cancer screening reduces breast cancer mortality at 
the population level, subgroups of women may benefit differently. We investigated 
the impact of health status on the effect of breast cancer screening.
Methods: The study included 181  299 women invited in two population-based 
screening programs in Denmark and 1 526 446 control subjects, followed from April 
1981 to December 2014. Poisson regressions were used to compare the observed 
breast cancer mortality rate in women invited to screening with the expected rate in 
the absence of screening among women with and without chronic diseases. Chronic 
diseases were defined as any diagnosis in the Charlson Comorbidity Index during 
4 years before the first invitation to screening.
Results: Almost 10% of women had chronic diseases before first invitation to screen-
ing. Whereas we observed a reduction in breast cancer mortality following invitation 
to screening of 28% (95% CI, 20% to 35%) among women without chronic diseases, 
only a 7% (95% CI, −39% to 37%) reduction was seen for women with chronic dis-
eases (P-value for interaction = .22). For participants, the reduction, corrected for 
selection bias, was 35% (95% CI 16% to 49%) for women without, and 4% (95% CI 
−146% to 62%) for women with chronic diseases (P-value for interaction = .43).
Conclusion: Our data indicate a marginal effect of mammography screening on 
breast cancer mortality in women with chronic diseases. If our results are confirmed 
in other populations, the presence of chronic diseases will be an important factor to 
take into consideration in personalized screening.
K E Y W O R D S
breast cancer mortality reduction, Breast cancer screening, chronic diseases, impact of screening, 
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Attempts are currently made to move screening from the 
“one model fits all” to more personalized screening. Models 
for prediction of breast cancer risks are now being developed 
to form a more comprehensive basis for personalized screen-
ing.4,5 Besides breast density, these models include family 
history of breast cancer, life style factors, and genetic variants. 
Screening trials based on such models are currently under way 
as the American WISDOM study6 and the European MyPEBS 
study,7 where women are randomized to either a personalized, 
risk-based screening strategy or to routine screening.
Here we investigated the potentials for personalized screen-
ing from a different perspective. We focused on the impact of 
health status on the actual outcome of screening, comparing 
women who had with women who had not been offered screen-
ing, stratified by health status. Several studies have shown that 
comorbidity increases mortality from breast cancer as well as 
all-cause mortality.8-10 Women with severe comorbidities are 
less likely to receive appropriate treatment than women with-
out comorbidities.10,11 However, due to their comorbidities 
and consequently their high risk of dying from other causes 
of death, even appropriately treated women may not live long 
enough to benefit from early detection and treatment. In a re-
cent study, Demb et al found that older, screened women with 
comorbidity had a higher risk of dying from other cause of 
death than older, screened women without comorbidity, but 
the risk of being diagnosed with or dying from breast cancer 
was the same in the two groups.12 These results suggested a 
limited benefit of breast cancer screening in older women with 
comorbidities, but the actual effect remains untested.
In the present study, we tested whether the presence of 
chronic disease modified the effect of screening on breast 
cancer mortality in women invited to population-based 
screening in Denmark, using individual-level data.
2 |  MATERIALS AND METHODS
2.1 | Breast cancer screening program
In Denmark, organized breast cancer screening programs 
started in Copenhagen municipality on 1 April 1991 and in the 
county of Funen on 1 November 1993. These two pioneer pro-
grams covered 20% of Danish women and invited to screen-
ing every second year women aged 50 to 69 years. Screening 
in the rest of Denmark was implemented in 2007-2008.
2.2 | Study and control groups
Thanks to the gradual implementation of breast cancer screen-
ing, Denmark can be seen as a “natural experiment” with 
screened and non-screened regions (Table S1). Hence, this 
setting allowed for both regional and historical comparisons. 
Briefly, the design consisted of one study group of birth co-
horts invited to screening; and of three control groups: a re-
gional control group including the same birth cohorts from 
regions of Denmark where screening was not implemented; 
a historical control group including birth cohorts from the 
screening regions prior to screening; and a historical, re-
gional control group including birth cohorts from the non-
screening regions in this historical period. Figure 1 represents 
the Lexis's diagrams for women included in the study.
The study group included women invited to screening in 
the Copenhagen pioneer program between 1 April 1991 and 
31 December 2007, and women invited to the Funen pioneer 
program between 1 November 1993 and 31 December 2007. 
Women were included from their first date of invitation to 
screening. The regional control group included women living in 
non-screening regions of Denmark during the same period. We 
followed women in these groups until 31 December 2014, except 
for women born after 31 December 1937 that were followed only 
until 31 December 2007, when they started to be invited in the 
national screening program (Figure 1, Method S1 and Table S2).
We used two historical control groups; first, women living 
prior to screening in Copenhagen between 1 April 1981 and 
31 March 1991 or in Funen between 1 November 1981 and 
31 October 1993 (the historical study group); second, women 
living in non-screening regions (historical, regional control 
group) during the same period. We followed women in the 
historical groups until the start of the pioneer programs, that 
is 31 March 1991 for Copenhagen and until 31 October 1993 
for Funen. However, women living in Copenhagen born be-
fore 1 April 1921 (and women living in Funen born before 1 
November 1923) were followed until 31 December 2004, as 
these women were already above screening age when the na-
tional program started (Figure 1, Method S1 and Table S2).
We allocated a pseudo-invitation date to women in the 
control groups, following the algorithm used for the study 
group. In all groups, we excluded women diagnosed with 
breast cancer before first invitation (pseudo-invitation).
We used the three control groups to estimate the expected 
outcome in the absence of screening. The expected outcome 
in the absence of screening was estimated by the outcome in 
the non-screening region (regional control group) controlling 
for historical differences between the outcome in the screen-
ing region (historical study group) and the outcome in the 
non-screening region (historical, regional control group). In 
this way, we controlled for differences between regions and 
changes over time that could affect breast cancer mortality. 
This study design has been described in detail previously.3,13
2.3 | Data source
Individual data on vital status and current and historical ad-
dresses were retrieved from the Danish Central Population 
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Register.14 We identified breast cancer diagnoses from the 
Danish Cancer Register,15 and underlying causes of death 
from the Danish Cause of Death Register.16 Data on dates of 
invitation and screening attendance were received from the 
screening registers in Copenhagen and Funen. We retrieved 
information on chronic diseases from the Danish National 
Patient Register,17 which includes diagnoses for all in-patient 
contacts to Danish hospitals somatic wards since 1977, and 
for all out-patient contacts, and in-patient contacts to psychi-
atric wards since 1995. Diagnoses are classified according 
to the International Classification of Disease, 8th revision 
(ICD-8) until the end of 1993 and 10th revision (ICD-10) 
thereafter. We linked the data using the personal identifica-
tion number assigned to all residents in Denmark.
2.4 | Chronic diseases data
All discharge diagnoses (primary, secondary, and additional 
diagnoses) during the 4  years before invitation (pseudo-
invitation) to screening were used to detect the presence 
of chronic diseases included in the Charlson Comorbidity 
Index.18 These diseases included liver diseases, myocardial 
infarction, congestive heart failure, peripheral vascular dis-
ease, chronic pulmonary disease, cerebrovascular disease, 
hemiplegia, dementia, connective tissue disease, ulcer dis-
ease, diabetes, renal disease, cancer, and HIV/AIDS, see 
Table S2 in the Supplementary Data for ICD codes. We ex-
cluded codes for breast cancer because the population was 
breast cancer-free at the start of follow-up. Women were 
categorized as having no or one or more chronic diseases at 
beginning of follow-up.
2.5 | Outcomes
We assessed breast cancer mortality defined as death from 
breast cancer (ICD-8; 174 and ICD-10; C50, D50).
2.6 | Statistical analysis
We tabulated women by age (50-54, 55-59, 60-64, 64-69, 70-
74) and prevalent chronic diseases at beginning of follow-up.
To analyze the effect of invitation to screening, we mod-
eled a Poisson regression comparing the observed breast 
F I G U R E  1  Study design illustrated in Lexis’ diagrams. The groups were constructed using the date of birth and current and historical 
addressees retrieved from the Danish Central Population Register. The areas surrounded by the solid line represent the (pseudo-) screening period, 
and the areas surrounded by the dotted line the (pseudo-) after screening period. The former and the latter represent the follow-up period.
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cancer-specific mortality rate in women invited to screen-
ing with the expected rate in the absence of screening,3 see 
Method S2 in the Supplementary Data. This analysis was 
made separately for women having no and for women having 
one or more chronic diseases.
We used the “Evaluation model” conceptualized by 
Nyström et al19 and Beau et al3 The model includes breast 
cancer deaths in women diagnosed with breast cancer 
during screening age (ie, we added 6 months to allow time 
for diagnosis), and equivalent for the control groups. For 
women of screening age, person-years were accumulated 
from date of invitation (or pseudo-invitation) until date of 
death, emigration, or end of follow-up, whichever came 
first. For women after screening age, person-years were ac-
cumulated in the same way but only for women with breast 
cancer diagnosed during screening age. This model mini-
mizes the dilution of the screening effect from breast cancer 
deaths in patients diagnosed after end of screening age.3 
We assessed the effect modification by health status using 
a likelihood ratio test.
We conducted supplementary analyses on women partici-
pating at first invitation to screening using the method by 
Duffy et al.20 The rate ratio for participants compared with 
that of nonparticipants was adjusted for the increased breast 
cancer mortality rate in nonparticipants calculated as: RR2 = 
p휓Dr
1−(1−p)Dr
, where p denotes the proportion of participants at first 
invitation to screening, 휓 is the estimated rate ratio for partic-
ipants compared with nonparticipants, and Dr is the rate ratio 
for nonparticipants compared with uninvited control groups.
Results were adjusted by current age (divided into 5-year 
age group) and expressed as rate ratios (RR) with two-sided 
and 95% confidence interval (CI). We analyzed data using 
SAS version 9.4 (SAS Institute Inc, Cary, NC).
It was not possible to calculate the power of the study be-
forehand as we did not know the size of the group of women 
having chronic diseases before we had linked and edited all 
the register data.
3 |  RESULTS
The study was based on 12 598 866 person-years, 1 421 769 
from women invited to screening, and 11 177 097 from con-
trol subjects.
Overall, the mean age at beginning of follow-up was 
57.0 ± 6.2 years. The prevalence of chronic diseases before 
first invitation (pseudo-invitation) to screening was 7% to 9% 
(Table 1), with vascular disease, chronic pulmonary disease, 
and cancer (other than breast cancer) as the most common.
For the study group as a whole, we observed a 26% re-
duction in breast cancer mortality after invitation to screen-
ing (age-adjusted RR = 0.74 (95% CI, 0.66-0.82); Table 2). 
However, the effect of invitation to screening on breast 
cancer mortality was only 7% in women with chronic dis-
eases (age-adjusted RR = 0.93 (95% CI, 0.63-1.39)), whereas 
the effect was 28% in women without chronic diseases 
(age-adjusted RR  =  0.72 (95% CI, 0.65-0.80)). The differ-
ence between the two groups of women did not reach statisti-
cal significance (P-value for interaction = 0.22).
Participation at first invitation to screening was 71% 
among women with chronic diseases versus 77% among 
those without (Table  3). For women with chronic diseases 
before follow-up, the RR of breast cancer mortality was 0.70 
(95% CI, 0.43-1.13) for participants at first invitation, the 
RR for nonparticipants was 1.25 (95% CI, 0.74-2.09), and 
the corrected RR of dying from breast cancer for participants 
with chronic diseases became 0.96 (95% CI, 0.38-2.46). For 
women without chronic diseases, the RR for participants was 
0.51 (95% CI, 0.44-0.59), and 1.21 (95% CI, 1.04-1.40) for 
nonparticipants, and the RR of dying from breast cancer for 
participants without chronic diseases became 0.65 (95% CI, 
0.51-0.84). The difference between the two groups of par-
ticipants did not reach statistical significance (P-value for 
interaction = 0.43).
4 |  DISCUSSION
We observed that invitation to organized, population-based 
screening was associated with a reduction of only 7% in 
breast cancer mortality among women with chronic diseases, 
while a 28% reduction was observed among women with-
out chronic diseases. Attendance to screening was lower in 
women with than in women without chronic diseases, but the 
difference in effect of screening among participants was even 
larger than for all invited women. After controlling for selec-
tion bias, participating women with chronic diseases expe-
rienced a 4% reduction in breast cancer mortality, while the 
reduction was 35% among participants without chronic dis-
eases. The Danish screening programs invited women aged 
50 to 69 years old, and only 9% of invited women suffered 
from chronic diseases. Despite the large difference observed 
in the effect of screening between women with and women 
without chronic diseases, our groups were too small for the 
difference to reach statistical significance.
A limited effectiveness of screening in women with 
chronic diseases might be expected. First, already before in-
vitation to screening women with chronic diseases may be 
under clinical surveillance with the possibility of having 
early symptoms of breast cancer investigated. Nevertheless, 
we cannot separate out a possible effect of clinical surveil-
lance from a possible effect of a higher breast cancer risk, for 
example in women with diabetes.21 Secondly, breast cancer 
patients with chronic diseases may have received less optimal 
treatment than women without chronic diseases, as clinicians 
may be concerned about the toxicity of treatment, treatment 
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might be less effective, or life expectancy might be judged 
too short to justify treatments10,11 Using Danish data, Land 
et al reported that breast cancer patients with comorbidities 
were less likely than those without to be enrolled in treat-
ment protocols; 57% vs 76%.22 Thirdly, breast cancer patients 
with chronic diseases may have benefitted less from a given 
treatment than those without chronic diseases. The data on 
efficacy of breast cancer treatment derive mainly from ran-
domized control trials where women with comorbidities 
are, mostly, excluded. However, using observational studies, 
Land et al showed that patients with comorbidities who actu-
ally received adjuvant treatment benefitted to the same extent 
as patients without comorbidity.22,23 Finally, the effective-
ness of screening depends on the sensitivity of the test. We 
estimated the sensitivity of the Copenhagen program as the 
proportion of screen-detected cancer out of all breast cancer 
diagnosed within 24 months of the first invitation (or before 
the next screen). We found the sensitivity to be slightly lower, 
but not statistically different, among women with chronic dis-
eases 56% (95% CI, 45%–66%) than for women without 66% 
(95% CI, 63%–70%). Sensitivity is often used as a short-term 
indicator of screening effectiveness,24 and our results indi-
cate that sensitivity by health status at invitation may be an 
indicator for the expected effect of screening on breast cancer 
mortality.
Age at screening has been a key topic in the investiga-
tion of differential effects of screening on breast cancer 
mortality,1 but few studies have focused on other factors. In 
a case-control study nested in a population-based screening 
program in Nijmegen, the Netherlands, Ripping et al25 found 
the reduction in breast cancer mortality to be slightly stron-
ger, but nonsignificantly, in women with low than in women 
with high socioeconomic status, and Waal et al26 found a 
smaller breast cancer mortality reduction among women 
with dense than among women with fatty breasts. Demb 
et al estimated the 10-year risk of invasive breast cancer, 
T A B L E  1  Number of women invited to breast cancer screening in two early, organized programs in Denmark (study group), and number of 
women in three control groups; number of women by age, and number of women with chronic diseases
 
Study Group 
(N = 181 299)
Regional Control Group 
(N = 822 370)
Historical Study Group 
(N = 162 518)
Historical, Regional Control 
Group (N = 541 558)
Age category at beginning of follow-up, N(%)
50-54 yr 105 109 (57.98)a 517 886 (62.97) 63 700 (39.20) 242 211 (44.72)
55-59 yr 25 464 (14.05) 101 036 (12.29) 29 406 (12.09) 101 037 (18.66)
60-64 yr 23 793 (13.12) 93 279 (11.34) 32 470 (19.98) 95 106 (17.56)
65-69 yr 23 464 (12.94) 90 063 (10.95) 32 066 (19.73) 84 357 (15.58)
70-74 yr 3469 (1.91) 20 106 (2.44) 4876 (3.00) 18 847 (3.48)
Chronic diseases at beginning of follow-upb , N (%)
No chronic diseases 165 749 (91.42) 761 389 (92.58) 151 161 (93.01) 504 034 (93.07)
One or more chronic 
diseases
15 550 (8.58) 60 981 (7.42) 11 357 (6.99) 37 524 (6.93)
Vascular disease 4308 (2.38) 17 784 (2.16) 3318 (2.04) 11 523 (2.13)
Dementia 162 (0.09) 532 (0.06) 216 (0.13) 518 (0.10)
Chronic pulmonary 
disease
3358 (1.85) 12 199 (1.48) 1813 (1.12) 5991 (1.11)
Connective tissue 
disease
1784 (0.98) 7885 (0.96) 11 411 (0.87) 4628 (0.85)
Ulcer disease 1408 (0.78) 6086 (0.74) 1279 (0.79) 4488 (0.83)
Diabetes 1 and 2 2586 (1.43) 8852 (1.08) 1542 (0.95) 5469 (1.01)
Liver disease 844 (0.47) 2395 (0.29) 547 (0.34) 1267 (0.23)
Hemiplegia 61 (0.03) 336 (0.04) 83 (0.05) 286 (0.05)
Moderate to severe 
renal disease
411 (0.23) 1602 (0.19) 407 (0.25) 1554 (0.29)
Cancerc 3106 (1.71) 12 668 (1.54) 2600 (1.60) 8168 (1.51)
AIDS 35 (0.02) 34 (0.00) 0 (0.00) d 
a324 women were less than 50 years at invitation to screening. 
bDuring the 4 years before invitation (pseudo-invitation) to screening, women can have more than one chronic disease. 
cBreast cancer diagnosis was not counted. 
dThree or less individuals. 
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breast cancer death, and other cause of death according to 
comorbidity and age among women screened at ages 66 to 
94 years without a history of breast cancer.12 As expected, the 
non-breast cancer-related mortality increased with increasing 
comorbidity. As expected, the breast cancer mortality was 
low in these women who were breast cancer-free at the time 
of recruitment, and it did not vary across comorbidity group. 
These results support the findings from the Swedish random-
ized trials, showing that breast cancer deaths constitute only 
a small proportion of all deaths.27 The Demb et al data cannot 
directly be compared with our data because it include women 
screened up to age 94  years, which is far beyond the stop 
of screening at age 69 years in Denmark. Moreover, Demb 
et al did not test the differential effect of screening between 
women with and without chronic diseases.
For the population at large, a meta-analysis of random-
ized control trials from the US and Sweden estimated that to 
prevent one breast cancer death per 1000 screened women, 
the women should have a remaining life expectancy of at 
least 10 years.28 Some US screening guidelines, for instance 
from the American Cancer Society,29 recommend stopping 
screening in women with a remaining life expectancy of less 
than 10 years, while Europe screening guidelines are based 
solely on age.2 In any case, assessing the remaining life ex-
pectancy of a woman is challenging. Hence, the burden of 
chronic diseases of an individual might be the best proxy 
for the remaining life expectancy. For instance, studies have 
used comorbidity scores to develop comorbidity-adjusted life 
expectancy tables.30,31 Moreover, mortality indices that take 
into account age and medical conditions have been used in 
clinical practice to predict the 4- to 10-years mortality.32,33 
These studies highlight that the health status could help in 
tailoring cancer screening decisions. Our approach, based 
on the presence or absence of chronic diseases, might be a 
more direct way to distinguish women likely to benefit from 
screening from those not likely to benefit. Information on the 
presence of diseases is easily available either from asking the 
woman or, as in our case, from national health registers.
Without partitioning our population based on the pres-
ence or absence of chronic diseases prior to screening, we 
found a 26% breast cancer mortality reduction in women 
invited for screening and a 33% reduction in screened 
women. These results are in line with previous evidence 
as reported by the IARC report.24 Our analysis in women 
with chronic diseases at the time of invitation to screen-
ing showed little impact of screening in this population. 
This result is new, and further research is needed to test 
our findings. If similar patterns are observed, the presence 
of chronic diseases is an important factor to consider in 
personalized screening. Individualized decision-making 
approaches, for instance, taking into account the severity 
of the chronic diseases, the likelihood to tolerate breast 
cancer treatment, the women's age and preferences, might 
be offered to women with chronic diseases to improve their 
potential benefit from screening and to optimize the health-
care resources.
Moreover, more knowledge of harms of screening is 
needed for building a complete picture of the screening bal-
ance for women with chronic diseases. In a modeling study 
using data from England and Norway, Falk and Hofvind esti-
mated that in a population offered screening, between 2% and 
4% of women diagnosed with breast cancer would die from 
other causes within the estimated lead-time.34 Owing to the 
reduced life expectancy, we expect this inevitable proportion 
of overdiagnosed breast cancer cases to be larger in women 
with than in women without chronic diseases.
4.1 | Limitations and strengths
Our study has limitations. The Charlson Comorbidity 
Index18 identified from hospital records may not capture 
all diseases associated with breast cancer mortality; some 
women with chronic diseases but without hospital con-
tacts during the last 4  years may be misclassified to the 
no chronic diseases group. Thus, it underestimated the true 
difference between the two groups. In addition, our study 
was based on a young population at beginning of follow-up 
limiting the size of the group of women with chronic dis-
eases. A broad range of diseases is included in the Charlson 
Comorbidity Index; however, due to the relatively small 
size of the group of women with chronic diseases, we were 
not able to study subgroups. Lastly, the denominator in 
our calculation of the post-screening rate of breast cancer 
mortality could potentially have been inflated if we had 
many nonlethal overdiagnosed breast cancer cases, but in 
Denmark, with sufficient time for post-screening follow-
up, overdiagnosis was estimated to account for only 2.3% 
of breast cancer cases.35
The strengths of our study are the cohort design with 
inclusion of a study group invited to screening and three 
control groups not invited to screening, and use of individ-
ual linkage between registers with complete follow-up of 
all groups. In our data, the study group includes only obser-
vations from women actually targeted by screening. This 
is in contrast to routine statistics data, like NORDCAN, 
where the tabulation by age groups will include obser-
vations from many women not targeted by screening. 
Opportunistic screening was rare in Denmark, ensuring 
that there was very little contamination of screening in 
the control groups.36 Data used to derive women's health 
status before follow-up were from a national register with 
complete registration of hospital contacts. Furthermore, 
the Charlson Comorbidity Index is a validated tool, which 
has been used intensively, allowing for comparison of our 
findings with previous studies.
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In conclusion, among women without chronic diseases, we 
observed a 28% reduction in breast cancer mortality follow-
ing invitation to screening. However, the reduction was only 
7% among women with chronic diseases. This difference 
was even larger among participants with a 35% reduction for 
women without and 4%  for women with chronic diseases. 
Even though the differences between the groups did not reach 
statistical significance, our data indicate that not only the ex-
pected risk of breast cancer but also the expected benefit and 
harm from participating in screening might be considered in 
personalized screening.
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